MAGEA1 and hepatocellular carcinoma: Among the 58 HCC patients studied, 37.93% (22/58) responded to SALL4, 32.76% (19/58) to MAGE-A3, 23.40% (11/47) to MAGE-A1, 10.64% (5/47) to NY-ESO-1, 10.64% (5/47) to SSX2, and 37.93% (22/58) to AFP.